[Endoscopic, histologic and morphometric evaluation of the gastric mucosa in patients with osteoarthritis treated with piroxicam and zinc acexamate].

What Was Tested

This randomized controlled trial looks at Piroxicam.

Zinc acexamate (ZAM) is an antiulcer agent with antisecretory and gastroprotective properties.

Clinical controls were undertaken on days 0, 14, 28 and endoscopic and histologic controls performed on days 0 and 28.

Who Took Part

The study group was 2 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The patients were allocated by chance, so the Piroxicam group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Piroxicam, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Piroxicam could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Aminocaproates, Aminocaproic Acid, Anti-Inflammatory Agents, Non-Steroidal, Anti-Ulcer Agents, Gastric Mucosa, Gastrointestinal Diseases and Gastroscopy.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Piroxicam in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1998 (Gastroenterologia y hepatologia), a journal based in Spain.

More context: all human trials.